Enrique (@Der_Dividenden_Monteur) sur getquin

6J·

Reallocation in the portfolio:

The decision was not easy, as I am still convinced of Meditec, but unfortunately the market simply sees things differently at the moment.

I see more upside for ASML as a shovel seller and more downside for Meditec with the possible tariff war between USA - Europe - China ( Asia accounts for a third of sales in 2023 according to Trading View )

Meditec remains on the watch while I wait for the quarterly figures on 11.12

18.11

ASML

Acheté x1 à 623,60 €

623,60 €

11 Commentaires

Soprano@Soprano

Do you really only have 1x ASML share and that's 8% of the portfolio?

I don't think the reallocation will make a big difference. As long as the semiconductor machinery industry continues to take each other into custody, nothing will happen with ASML. It doesn't matter at the moment whether you have ASML or KLA, LAM, Aixtron, Applied Materials, none of them are finding a buyer at the moment.

This is very similar to AFX, where there is also a weakness in the overall market, which is also affecting industry colleagues such as Thermo Fisher, Edwards Lifesciences etc. With the exception of Stryker, medical technology is generally not doing so well at the moment.

The upside should be the same for both. If nobody needs shovels at the moment, there is no point in being an alleged shovel seller. ASML's exposure to China is also 34%, so it's really a hop, skip and a jump. And here, too, export bans would hit ASML hard.

The only difference you might see is that you have to think about which area is more in focus: Medtec or semiconductors? When the trade war comes, it is usually not waged as a major offensive, but affects strategic sectors such as the steel industry, vehicles, etc.

•

Voir toutes les 7 autres réponses

ThemenmitKopf@topicswithhead

I don't understand the reasoning at all. Isn't most of ASML's products manufactured in Europe and the share is already very well valued and could fall significantly over the course of the year. After all, Carl Zeiss has been doing badly for a long time, so it's understandable

•

Voir toutes les 2 autres réponses